Cybin IncChange company Symbol lookupSelect an option...CYBN Cybin IncREXR Rexford Industrial Realty IncDYNT Dynatronics CorpEBET Ebet IncOMH Ohmyhome LtdATHX Athersys IncKEYS Keysight Technologies IncOPRA Opera LtdROIV Roivant Sciences LtdGPCR Structure Therapeutics IncGo
Based in Canada
Cybin Inc. (Cybin) is a clinical-stage biopharmaceutical company. The Company is engaged in creating psychedelic-based therapeutics to address the unmet need for new treatment options for people who suffer from mental health conditions. Its development pipeline consists of deuterated psilocybin analog program (CYB003), deuterated dimethyltryptamine program (CYB004), phenethylamine derivatives program (CYB005), and technology programs. The Company is engaged in developing CYB003, a deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The Company's CYB005 is focused on the development of therapeutic phenethylamine derivatives for the treatment of potential neuroinflammation and other neurological conditions. Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.
|
|
|
|
| |
Company Profile
Cybin Inc. (Cybin) is a clinical-stage biopharmaceutical company. The Company is engaged in creating psychedelic-based therapeutics to address the unmet need for new treatment options for people who suffer from mental health conditions. Its development pipeline consists of deuterated psilocybin analog program (CYB003), deuterated dimethyltryptamine program (CYB004), phenethylamine derivatives program (CYB005), and technology programs. The Company is engaged in developing CYB003, a deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The Company's CYB005 is focused on the development of therapeutic phenethylamine derivatives for the treatment of potential neuroinflammation and other neurological conditions. Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.
Valuation Ratios
- Price/Earnings (TTM)
- --
- Price/Sales (TTM)
- --
- Price/Book (MRQ)
- 3.50x
- Price/Cash Flow (TTM)
- --
MRQ = Most Recent Quarter
Price Performance
Financial Statements
Balance sheet
Values displayed are in thousands.
Income statement
Values displayed are in thousands.
Cash flow
Values displayed are in thousands.
Company Officers
No company officers listed.
Address
- 100 King Street West, Suite 5600
- Toronto, ON M5X 1C9
- Canada
- Phone: 6048060626
- Fax: 6048060626
- https://www.cybin.com
Insider Trading
No insider trading activity.
Insider trading information report provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.